Drug sensitivity pattern (first line ATT) in DOTS failure & relapse cases (Cat I & Cat II) rntcp, India

G.N. Srivastava, M. Meena, P. Yadav, J. Meena, M. Hussain (Varanasi, India)

Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Session: Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Session type: Thematic Poster Session
Number: 2682
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G.N. Srivastava, M. Meena, P. Yadav, J. Meena, M. Hussain (Varanasi, India). Drug sensitivity pattern (first line ATT) in DOTS failure & relapse cases (Cat I & Cat II) rntcp, India. Eur Respir J 2012; 40: Suppl. 56, 2682

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Chronic alcoholics[scquote] (CA) knowledge (KN) and social stigmatisation (ST) regarding tuberculosis (TB)
Source: Eur Respir J 2001; 18: Suppl. 33, 322s
Year: 2001

Late Breaking Abstract - Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO
Source: Virtual Congress 2021 – COVID-19 acute respiratory distress syndrome
Year: 2021



Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA
Source: Eur Respir J 2004; 24: Suppl. 48, 8s
Year: 2004

The results of drug resistance survey of MDR-strains on second line drugs obtains in national reference laboratory – " M.Nasta " Institute – Bucharest
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011

Tuberculosis (TB) relapse rate among patients treated with moxifloxacin (m) or ethambutol (E) in the intensive phase of therapy
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009


The impact of antimicrobial resistance on the cost-effectiveness of empirical treatment of community-acquired pneumonia (CAP) in France (FR), Belgium (BE) and Germany (DE)
Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication
Year: 2007


Asthma control in Latin america (LA) and Caribbean (CAR) countries: correlation between asthma control test (ACT), FEV1 and current treatment
Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Year: 2009


Accuracy of EGFR and K-Ras mutation detection in non small cell lung carcinoma: Ring trial in 15 molecular French laboratories (ERMETIC project – Part 1)
Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Year: 2010


Asthma control (AC) 1 year after pulmonary rehabilitation (PR)
Source: Annual Congress 2011 - Challenges in rehabilitation: some old dilemmas revisited with some solutions?
Year: 2011


A retrospective study of the indications for the use of interferon gamma release assays (IGRA) in a United Kingdom (UK) district general hospital (DGH) tuberculosis (TB) clinic
Source: International Congress 2015 – Screening strategies in TB
Year: 2015


Tuberculosis (TB), mortality - efficiency of new control / treatment strategies
Source: Annual Congress 2003 - Control of tuberculosis
Year: 2003


Effect of resistance training (RT) on maximal exercise capacity (MEC) and muscle force (MF) in patients (pts) with radically treated (RaT) intrathoracic cancer
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013

Clinical pattern of extrapulmonary tuberculosis (EPT) as observed at a teaching hospital in India – are we missing them?
Source: Annual Congress 2009 - Pulmonary infections
Year: 2009


Regional reference centre for multi-drug resistant tuberculosis – 11 months of activity
Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis
Year: 2010


Patients with culture positive active tuberculosis but negative "QuantiFERON-TB Gold in Tube Test" (QFT) – A critical view on the cut-off in clinical praxis
Source: Annual Congress 2010 - Immune responses for the diagnosis of tuberculosis
Year: 2010


Doctors (drs) knowledge of diagnosing, investigating & managing pulmonary embolus (PE) in pregnancy?
Source: Annual Congress 2009 - Pulmonary embolism
Year: 2009

Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia)
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB)
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools
Year: 2012


Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: LUX-Lung 7
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016